Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone - Neuschwander-Tetri, BA; Brunt, EM; Wehmeier, KR; Oliver, D; Bacon, BR (Hepatology, 2003)